Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Emcure Pharmaceuticals Ltd. Share Price
Day's Range
Low
₹1,931.50
High
₹1,976.90
Price Summary
| Previous Close | ₹1,950.60 |
|---|---|
| Day's Range | ₹1,931.50 - ₹1,976.90 |
| Open | ₹1,958.70 |
| 52 Week Range | ₹1,260.00 - ₹2,100.70 |
| Volume | 32,384 |
| Market Cap | ₹0.04 |
| Previous Close | ₹1,945.15 |
|---|---|
| Day's Range | ₹1,931.00 - ₹1,972.80 |
| Open | ₹1,954.95 |
| 52 Week Range | ₹1,260.10 - ₹2,101.00 |
| Volume | 3,515 |
| Market Cap | ₹0.04 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 630.96 |
|---|---|
| Market Cap (₹ in Mn) | 0.04 |
| Dividend Yield(%) | 0.19 |
| Price/Earning (TTM) | 36.49 |
| TTM EPS (₹) | 53.31 |
| P/E Ratio | 32.73 |
| Book Value(₹) | 7.05 |
| PAT Margin (%) | 10.02 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 25.25 |
| Trade Value ( ₹ in Lacs) | 68.52 |
|---|---|
| Market Cap (₹ in Mn) | 0.04 |
| Dividend Yield(%) | 0.19 |
| Price/Earning (TTM) | 36.49 |
| TTM EPS (₹) | 53.31 |
| P/E Ratio | 32.73 |
| Book Value(₹) | 7.05 |
| PAT Margin (%) | 10.02 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 25.25 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 10965.73 | 78959.97 |
| Expenses | N/A | N/A |
| PBT | 1656.69 | 9713.49 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 1227.89 | 7074.67 |
About Emcure Pharmaceuticals Ltd.
| Founded | 1981 |
|---|---|
| Managing Director | Satish Mehta |
| NSE Symbol | EMCURE |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,44,716.74 | 1,853.50 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 2,55,115.31 | 9,610.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,89,613.38 | 4,985.00 | 3,480.60 - 3,480.60 |
| Apollo Hospitals Enterprise Ltd. | 1,27,823.12 | 8,889.90 | 6,696.50 - 6,696.50 |
| Zydus Lifesciences Ltd. | 1,19,899.96 | 1,202.00 | 835.50 - 835.50 |
| Lenskart Solutions Ltd. | 1,18,325.00 | 682.80 | 0.00 - 0.00 |
| Cipla Ltd. | 1,12,875.68 | 1,397.20 | 1,165.70 - 1,165.70 |
| Laurus Labs Ltd. | 1,08,116.47 | 2,001.00 | 823.10 - 823.10 |
| Mankind Pharma Ltd. | 1,02,247.25 | 2,460.00 | 1,909.70 - 1,909.70 |
| Dr. Reddy's Laboratories Ltd. | 1,00,395.34 | 1,202.80 | 1,101.00 - 1,101.00 |
No Records Found
Latest News
Emcure Pharmaceuticals informs about acquisition
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘LODR Regulations’) and in furtherance to the disclosure made in the Prospectus filed with the Securities Exchange Board of India, during the Initial Public Offer of the Company, Emcure Pharmaceuticals has informed that Marcan Pharmaceuticals Inc., a subsidiary of the Company (‘Marcan’) has on July 02, 2026 (EDT) entered into share purchase agreements with certain shareholders of Mantra Pharma Inc., a step-down subsidiary of the Company (‘Mantra’), to acquire all of Class E Special Shares in the share capital of Mantra. Consequently, Mantra continues to be 100% subsidiary of Marcan. The particulars of the disclosure required under Regulation 30 and Part A of Schedule III of the LODR Regulations are provided in Annexure A, enclosed.
The above information is a part of company’s filings submitted to BSE.
Hindustan Bio Sciences informs about closure of trading window
Hindustan Bio Sciences has informed that the Trading window for dealing in the securities of the company will remain closed from 1st October 2026 till 48 hours after the announcement of standalone Un-audited Financial results for the quarter ending on September 30th 2026.
The above information is a part of company’s filings submitted to BSE.
Adeshwar Meditex informs about closure of trading window
Adeshwar Meditex has informed regarding closure of trading window for the quarter and half year ended September 30, 2026 pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.
The above information is a part of company’s filings submitted to BSE.
Desh Rakshak Aushdhalaya informs about change in directorate
Desh Rakshak Aushdhalaya has submitted intimation for re-appointment of Mr. Arihant Kumar Jain (DIN: 06401053) as whole-time director of the Company liable to retire by rotation in the 45th AGM of the Company pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The above information is a part of company’s filings submitted to BSE.
Tyche Industries informs about closure of trading window
Tyche Industries has informed that the Trading window of the Company shall remain closed w.e.f. October 1, 2026 till the expiry of 48 hours after the declaration of the Financial results of the Company for the 2nd quarter and half-year ended September 30, 2026.
The above information is a part of company’s filings submitted to BSE.
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Emcure Pharmaceuticals Ltd. is ₹1,950.60 as of 2026-09-25.
The market capitalisation of Emcure Pharmaceuticals Ltd. is ₹36,901.57 as of 2026-09-25.
The 1-year return of Emcure Pharmaceuticals Ltd. is 666.40% as of 2026-09-25.
The P/E ratio of Emcure Pharmaceuticals Ltd. is 32.73 as of 2026-09-27.
The 52-week high and low of Emcure Pharmaceuticals Ltd. are ₹2,100.70 and ₹1,260.00, respectively, as of 2026-09-25.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
